Sure. So we're very excited about the Phase III readout expected next quarter. Avexitide, our lead asset has been through 5 prior trials, all of which showed highly statistically significant effects on glucose and insulin. And then in the Phase II and Phase IIb, we studied the rate of Level 2 and Level 3 hypoglycemia, which showed quite a strong effect as well. So under that backdrop for the Phase III, our goal is to try to keep as much consistent as we possibly could. So very similar inclusion/exclusion cr ...

Amylyx Pharmaceuticals (NasdaqGS:AMLX) 2026 Conference May 13, 2026 04:40 PM ET Speaker0 Company presenter at the Bank of America Annual Healthcare Conference. My name is Jason Gerber. I cover pharm and biotech. I'm pleased to be introducing Amylyx Pharmaceuticals and Joshua Cohen, Co-Chief Executive Officer. This is an interesting time for Amylyx on the cusp of pivotal Phase III data expected in the 3rd quarter, a transformational event. I imagine a lot of our discussion is gonna be focused on the lead pro ...